The global cancer genomics consortium\u27s third annual symposium: From oncogenomics to cancer care by Costa, Luis et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications Biochemistry and Molecular Medicine
5-15-2014
The global cancer genomics consortium's third











Rajiv Gandhi Center for Biotechnology, Kerala, India
See next page for additional authors
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biochemistry, Biophysics, and Structural Biology Commons
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
Costa, L., Casimiro, S., Gupta, S., Knapp, S., Pillai, M.K. et al. (2014). The global cancer genomics consortium's third annual
symposium: From oncogenomics to cancer care. Genes and Cancer.
Authors
Luis Costa, Sandra Casimiro, Sudeep Gupta, Stefan Knapp, M. Radhakrishna Pillai, Mazakazu Toi, Rajendra
Badwe, Maria Carmo-Fonesca, and Rakesh Kumar
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs/
141
Genes & Cancer1www.impactjournals.com/Genes & Cancer
www.impactjournals.com/oncoscience/ Genes & Cancer, Advance Publications 2014
The global cancer genomics consortium’s third annual 
symposium: from oncogenomics to cancer care 
Luis Costa1,2,*, Sandra Casimiro1, Sudeep Gupta3,*, Stefan Knapp4,*, M. Radhakrishna 
Pillai5,*, Masakazu Toi6,*, Rajendra Badwe3,*, Maria Carmo-Fonseca1,*, and Rakesh 
Kumar7,*
1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
2 Hospital de Santa Maria – CHLN, Lisbon, Portugal
3 Tata Memorial Centre, Mumbai, India
4 Structural Genomic Consortium, University of Oxford, Oxford, UK
5 Rajiv Gandhi Center for Biotechnology, Kerala, India
6 Kyoto University Graduate School of Medicine, Japan
7 The George Washington University, Washington, DC, USA
* Member, The Global Cancer Genomics Consortium, Department of Biochemistry and Molecular Medicine, the George 
Washington University, Washington, DC, USA
Correspondence to: Rakesh Kumar, email: bcmrxk@gwu.edu
Keywords: Oncogenomics, Cancer Biomarkers, Cancer Therapy 
Received: May 3, 2014 Accepted: May 14, 2014 Published: May 15, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
The Global Cancer Genomics Consortium (GCGC) is a cohesive network of 
oncologists, cancer biologists and structural and genomic experts residing in six 
institutions from Lisbon, United Kingdom, Japan, India, and United States. The team 
is using its combined resources and infrastructures to address carefully selected, 
shared, burning questions in cancer medicine. The Third Annual Symposium was 
organized by the Institute of Molecular Medicine, Lisbon Medical School, Lisbon, 
Portugal, from September 18 to 20, 2013. To highlight the benefits and limitations of 
recent advances in cancer genomics, the meeting focused on how to better translate 
our gains in oncogenomics to cancer patients while engaging our younger colleagues 
in cancer medicine at-large. Over two hundreds participants actively discussed some 
of the most recent advances in the areas cancer genomics, transcriptomics and 
cancer system biology and how to best apply such knowledge to cancer therapeutics, 
biomarkers discovery and drug development, and an essential role played by bio-
banking throughout the process. In brief, the GCGC symposium provided a platform 
for students and translational cancer researchers to share their excitement and 
worries as we are beginning to translate the gains in oncogenomics to a better cancer 
patient treatment.
INTRODUCTION
The Global Cancer Genomics Consortium 
(GCGC) functions as a cohesive interface that aligns a 
multidisciplinary team of cancer and structural biologists, 
computational genomics experts, and oncologists to 
address shared global cancer research challenges through 
the application of high-throughput technologies using 
resources from its network. The GCGC is a dynamic 
initiative connecting members and their institutions from 
Lisbon, United Kingdom, Japan, India and United States. 
The GCGC network holds an annual meeting to discuss 
and debate the most pressing issues in cancer research 
and treatment, share their recent findings, exchange 
research ideas, and train students, young scientist and 
faculty members, in cutting-edge cancer genomics and 
need of cancer patients. The Third Annual Symposium 
was held at the Institute of Molecular Medicine, Lisbon 
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Medical School, Lisbon, Portugal, from September 18 to 
20, 2013, attracted 215 participants, and counted with 25 
invited platform speakers and 29 poster presenters. Once 
again, the GCGC Symposium brought together a highly 
motivated group of clinical and research cancer specialists 
and scientists, students and young researchers to share 
their latest results and ideas for translating the benefits of 
post-genomic advances in cancer medicine to improve the 
life of cancer patients. 
Focus on the Clinical Relevance of Oncogenomics
The third meeting was focused on the integration 
of the knowledge and translational strategies in the 
post–genomic era toward its clinical applicability. The 
symposium was opened by Prof. Luis Costa from the 
Institute of Molecular Medicine and Hospital de Santa 
Maria, and the introductory welcome remarks by Prof. 
Lobo Antunes from the same institution. Profs. Costa 
and Lobo Antunes shared the message of the Annual 
GCGC Symposium, emphasizing the importance of 
assessing the clinical relevance of knowledge that is 
being generated in post-genome-sequencing era with 
an overall goal to  develop effective diagnostic and 
therapeutic outcomes for cancer patients. The meeting 
was organized into eight platform sessions and one 
poster session, and included two keynote lectures. The 
symposium focused on eight major scientific and clinical 
themes: 1) breast cancer genomics and transcriptomics: 
where do we stand?; 2) current application of genomics 
in cancer therapy; 3) genomic approaches to facilitate 
biomarkers discovery and drug development; 4) genomics 
in clinics: biobanking; 5) innovative clinical trial designs 
in the era of cancer genomics; 6) application of cancer 
genomics research; 7) cancer system biology: cancer 
transcriptome, proteome and metabolome; and 8) how to 
integrate microenvironment and metabolomics with cancer 
genomics. The meeting concluded with a panel discussion 
about the future and next steps of GCGC research projects.
Breast Cancer Genomics and Transcriptomics: 
Where do We Stand? 
The theme was introduced by the opening keynote 
lecture by Dr. Clifford Hudis from the Memorial Sloan-
Kettering Cancer Center, and President of American 
Society of Clinical Oncology (ASCO). Dr. Hudis 
focused on the current role and future prospects of 
genomics and highlighted the need to broaden our 
understanding of genomic changes including complex 
and interacting alterations, functional alterations without 
conventional structural changes in solid tumors. He also 
stressed the possibility of considering even alternative 
or complimentary explanations for the growth of some 
malignancies. Dr. Hudis reinforced that clinicians and 
researchers need to be inclusive of a broader patient 
base and tumor acquisition supported by an improved 
bioinformatics for its eventual utility by all. Dr. Hudis 
concluded his lecture by sharing the ASCO’s CANCER 
LINQ project. 
Dr. Eric Winer from the Dana-Farber Cancer 
Institute focused on the contribution of genomics to the 
molecular diagnosis of breast cancer patients and their 
treatments. Until this point, the convergence of clinical 
and genomic data led to four families of breast cancer: 
the “basal-like”, the HER-2+; the Luminal B (estrogen 
positive with high proliferative index) and the Luminal 
A (estrogen positive with low proliferative index). Up 
to this moment, this sub-classification can be used to 
assess prognosis and to determine appropriate treatment 
toward a more personalized therapy. It has been also 
useful to drive research in order to assess changes in 
treatment response to each one of the sub-types, as well 
as to characterize better mechanisms of resistance to the 
available treatments and discover new “druggable” targets. 
Single gene changes responsible for somatic alterations 
or germ line mutations are also under the most desirable 
new findings in genomic research. For example, HER-2 
and BRCA genes alterations are the most relevant gene 
alterations with clinical impact. Mutations in the PI-3K 
pathway are among the most common mutations in breast 
cancer, particularly in ER positive and in HER2 positive 
tumors. However, despite of the fact that a large number 
of new drugs are in pipeline, only a handful options are 
advancing to the clinical scenario. 
Dr. Rakesh Kumar from the George Washington 
University focused on how RNA sequencing efforts could 
provide new insights into breast cancer transcriptome. 
The McCormick Genomic and Proteomic Center (MGPC) 
team has recently completed an extensive comparative 
analyses of triple-negative breast, estrogen receptor 
positive, and HER2 positive breast cancers and presented 
a comprehensive digital transcriptome [1]. This work led 
to identification of novel and unannotated transcripts, 
breast cancer sub-type specific transcriptomic adaptations, 
and clues about new set of modulators of breast cancer. 
Using in-house pipelines, the team also delineated splicing 
signatures and differentially spliced genes in human 
transcriptome. In general, distinct patterns of primary 
transcripts and promoter switching in breast cancer were 
identified and these molecular changes might contribute 
to the noted heterogeneity of breast cancer transcriptome. 
Using the same RNA-sequencing primary datasets, 
algorithms were also developed to recognize the genetic 
variance of breast cancer in the context of its allelic 
preferential expression, and splicing signatures. Together 
with Drs. Badwe and Gupta from the Tata Memorial 
Center Mumbai, Prof. Kumar’s team unlocked the 
transcriptomic insights of breast tumors from a subset of 
breast cancer patients were treated with a single injection 
of progesterone prior to the surgery [2]. Dr. Kumar also 
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presented results from on-going collaboration with the 
Institute of Molecular Medicine in Lisbon, where the team 
is revealing the transcriptome of bilateral breast cancer 
with different tumor types. 
Dr. Caterina Marchió from the Turim University 
addressed the gap between genomics and molecular 
pathology in the management of patients with breast 
cancer. Dr. Marchió highlighted new promises and 
challenges involved in on-going rapid integration of 
massive parallel next generation sequencing into clinical 
arena. In order to fill in the gap between genomics and 
modern pathology (which appears still conspicuous), 
tests will definitely play a role in diagnostic breast cancer 
pathology, it will be important for pathologists to be 
ready to integrate such developments into diagnostic 
breast cancer pathology while ensuring the best clinical 
management of breast cancer patients. 
To conclude this session, Dr. Nikhil Wagle 
from the Dana-Farber Cancer Institute discussed 
the use of systematic genomic profiling approaches 
– including hotspot genotyping, targeted massively 
parallel sequencing, and whole exome sequencing – 
to better understand the molecular determinants of 
tumorigenesis, characterize mechanisms of therapeutic 
response and resistance, and identify actionable genomic 
alterations to aid with clinical decision-making. These 
approaches include hotspot genotyping, targeted massively 
parallel sequencing and whole exome sequencing. Dr. 
Wagle also highlighted the need to test the “genomics-
driven” cancer medicine hypothesis through novel 
clinical trial design and centralized shared databases [3,4]. 
Dr. Wagle presented the initial results from the CanSeq 
initiative, collaboration between the Broad Institute, 
Dana-Farber, and Brigham and Women’s Hospital, on the 
prospective whole-exome sequencing for patients with for 
the benefits of clinically actionable results [5]. To conclude 
Dr. Wagle reinforced the notion that genomic profiling 
technologies are changing the way we will practice 
oncology by identifying new therapeutic opportunities as 
we can now identify common and rare genomic alterations 
(“the long tail”) in patients with cancer that might predict 
responses to novel targeted therapies. Although efforts are 
underway to implement tumor genomic profiling platforms 
in the clinical arena, the interpretation of genomic 
alterations and the incorporation of such data into clinical 
care continue to be challenging. The “genomics-driven” 
cancer medicine hypothesis is beginning to be tested – we 
need clinical trials and shared databases to best answer 
the question.
Application of Genomics in Cancer Therapy
The meeting brought together three leading experts 
to discuss emerging applications of genomic-driven 
findings to the cancer therapy. Dr. Carmo-Fonseca 
attempted to link cancer with altered expression of 
proteins implicated in the regulation of splicing machinery 
and suggested such molecules as potential targets for 
anticancer treatment. Dr. Carmo-Fonseca also shared some 
innovative data about the identification of splicing factors 
that are mis-regulated in cancers. Recurrent mutations 
in genes encoding essential components of the splicing 
machinery such as U2AF1 and SF3B1 are related to 
cancer. Dr. Carmo-Fonseca focused on the potential role 
of spliceostatin in blocking the formation of a catalytic 
spliceosome and raised the possibility of using such 
approaches in cancer therapeutics [6]. 
This was followed by Dr. Sudeep Gupta from the 
Tata Memorial Hospital presented a genetic/genomic 
perspective on gynecological cancers. Dr. Gupta focused 
on focus on ovarian cancer with a particular emphasis 
on high grade serous subtype. Dr. Gupta presented 
recent studies dissecting the molecular heterogeneity 
of ovarian cancer [7], and contributing to the new 
classification of ovarian cancer into the so called Type 
1 and Type 2 tumors [8]. From the genomic perspective, 
he highlighted the TCGA initiative and outlined the 
progress in our understanding of differences between 
different types of ovarian cancer in clinical presentation, 
genetic predisposition, hallmark molecular abnormalities, 
response to treatment and outcome. 
Dr. Raquel Seruca from IPATIMUP (Institute of 
Molecular Pathology and Immunology at the University 
of Porto) review the severe effects caused by CDH1 
pathogenic variants and discuss how these novel findings 
can be applied for the development of novel screening 
tools and the development of therapeutic strategies to treat 
patients harbouring carcinomas associated with the loss 
of E-cadherin. CDH1 germ line mutations and somatic 
alterations cause hereditary diffuse gastric cancer and have 
been extensively studied by Dr. Seruca and colleagues [9]. 
Genomic Approaches to Facilitate Biomarkers 
Discovery and Drug Development
The relevance of genomics in biomarkers and drug 
development was addressed in the next presentations. 
Dr. Masakazu Toi from the Kyoto University School 
of Medicine focused on how the development of new 
predictive biomarkers could help to maximize the 
treatment efficacy and mimic the burdens toxicity and cost 
of anti-HER2 therapy in breast cancer. The list of validated 
markers to predict treatment response continues to be 
limited considering the wealth of genomic information 
available. The search for markers which could effectively 
predict of response to MTOR inhibitors is on. This area 
of development is focused on the role of S6 kinase, 
PTEN status and PI3K mutation to predict the response 
to mTOR inhibitors. Dr. Toi underlined the importance of 
inter-observer concordance for IHC tests, such as the Ki-
67 proliferative index in breast cancer as the reliability of 
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Ki67 test in grade 2 tumors is not very clear at the moment 
as compared to high-expressing grade 3 tumors. 
Dr. João Nuno Moreira from the Center for 
Neuroscience and Cell Biology of University of Coimbra 
presented a new rationale for the to development of 
therapies -targeting tumor microenvironment on the basis 
of characterized mechanisms while improving access 
to intracellular sites of actions. Dr. Moreira stressed the 
potential of ligand-mediated targeted delivery as well as 
nanotechnologies-based approaches in the treatment of 
solid tumors such as breast cancer [10]. The systemic 
delivery of siRNA was also addressed [11]. 
Dr. Radhakrishnan Pillai from the Rajiv Gandhi 
Center of Biotechnology addressed the significance of 
cancer stem cell hypothesis, which puts forth that cancer 
cells have a hierarchical developmental structure in which 
only a fraction of cells termed cancer stem cells (CSCs) 
can proliferate indefinitely to form tumors. Dr. Pillai 
presented preliminary evidences for rare escape of tumor 
cells from drug induced cell death, after an intermediate 
stay in a non-cycling senescent stage followed by unstable 
multiplication. Dr. Pillai’s data suggested indicated that 
rare cancer cells escape from drug induced caspase 
activation by entering into a high ROS quiescence state 
followed by re-activation of anti-oxidant systems to 
help them to stabilize several transcription factors (such 
as NRF2 & OCT 4) and stem cell markers. Long term 
chemical hypoxia treatment could lead to expansion of 
drug efflux population and stabilization of HIF1-alpha 
while cells escaping hypoxia tend to be more invasive. Dr. 
Pillai concluded by presenting some new data on the use 
of this knowledge to design better screening methods for 
anti-cancer drug discovery. 
This session was ended by Dr. Luís Costa’s 
presentation, emphasizing the need of biology-driven 
clinical research to drug development wherein both 
the target and the disease model are equally important. 
Prof. Costa stressed that the success of biology-driven 
trials will be dependent on the discovery of reliable 
biomarkers. Dr. Costa believes that one of the great 
challenges to accelerate drug development in cancer care 
is the promotion of transversal-biology at the clinical and 
scientific level. Important information driven from biology 
and from clinical research observation can be transferred 
across different tumor types that share common driven-
events at different stages. Tumor-host bio-banking 
designed to address these hypothesis is crucial to support 
a transversal-translational-research. Dr. Costa also pointed 
how the GCGC mission to foster the creation of these 
multidisciplinary research teams an earlier intervention 
at the pre-graduation level would be desirable to develop 
both clinicians and scientists with transferable language 
and tasks.
Genomics in Clinics -Bio-banking
The theme was introduced by the opening keynote 
lecture by Dr. Carlos Caldas from the Cancer Research 
UK. Dr. Caldas made an exciting presentation highlighting 
the molecular characterization of 2,000 breast cancers to 
illustrate stratification of breast cancer into 10 subtypes 
with distinct biology and clinical outcomes. Genome-
wide copy number profiling of 997 tumors has revealed 
additional heterogeneity within the intrinsic sub-types 
of breast cancer. Joint clustering of copy number and 
expression data lead to a new molecular taxonomy of 
breast cancer. Such an approach improved prediction 
of outcome in ER+/HER2- cases and exhibited distinct 
prevalence and pattern of metastasis and sub-groups [12-
14]. 
The remainder of the session focused on the 
strict connection between research-driven tumor bio-
banking and the translational research outcomes. Dr. 
Fátima Carneiro from IPATIMUP and Hospital de 
São João emphasized a crucial role that pathologists in 
translational research by the establishment of a bridge 
between clinicians and basic researchers. Dr. Carneiro 
demonstrated why tumor banks are a vital resource for 
cancer research, using the example if the Portuguese 
National Network of Tumor Biobanks. 
Dr. Sandra Casimiro from Instituto de Medicina 
Molecular focused on her experience in colorectal cancer, 
bone metastases and breast cancer bio-banking. Dr. 
Casimiro presented a workflow for a successful strategy 
in tumor bio-banking, and demonstrated the different 
potential of project-driven tumor bio-banking versus the 
broad prospective collection of tumor specimens by a 
dedicated structure like Biobank IMM [15]. 
Next, Dr. Cláudia Faria from the Labatt Brain Tumor 
Research Center and Hospital de Santa Maria explained 
bio-banking primary brain tumors and brain metastases. 
She also summarized the mission of the Medulloblastoma 
Advanced Genomics International Consortium (MAGIC) 
and collaborative bio-banking activities at IMM involving 
tumor tissue, blood and plasma samples as well primary 
stem cell culture. 
Innovative Clinical Trial Designs in the Era of 
Cancer Genomics
This session debated the impact of cancer genomics 
in a “new” design of clinical trials. Dr. Nancy Lin from 
Dana-Farber Cancer Institute pointed the challenge in 
the screening and recruitment of patients in this new era 
of molecular stratification and addressed the question 
whether we are prepared or not to test new discoveries 
in cancer genomics. Testing new discoveries can be 
challenging for several reasons: testing is complex, 
requires novel methods only available in academic or 
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other specialized laboratories, asks for reproducibility, the 
object of testing is not routine; requires research consent 
and retrieval of tissue; potentially more tissue is required, 
there is higher likelihood of failure to obtain results; and 
the risk of “using up” tissue; frequently the turnaround 
takes time like weeks to months. Most important, there is 
only preclinical evidence and limited phase I data before 
initiation of proof-of-concept studies [16]. Finally, Dr. Lin 
suggested that some (if not most) of genomics data will 
be valuable in identifying resistance mechanisms and new 
targets that could be applied more broadly rather than in 
directing the care of individual patients. 
Dr. Alberto Bardelli from the University of Turim 
discussed on the molecular alterations in KRAS, NRAS, 
BRAF and MET and their association with the onset 
of acquired resistance to anti-EGFR blockade in colon 
cancer. Dr. Bardelli presented an optimized diagnostic 
platform to identify resistance-associated genetic 
alterations in the blood of patients (liquid biopsy) months 
before radiographic documentation of disease progression, 
providing the rationale for delaying or reversing resistance 
to anti EGFR therapies in colon cancer and such a model 
could be used for designing molecularly driven- clinical 
trials [17]. 
Dr. Ian Krop from Dana-Farber Cancer Institute 
approached the question whether the actual design of 
clinical trials is prepared to test the new discoveries of 
cancer genomics. The development of validated markers 
is crucial in this setting. The design of phase II biomarker-
driven trials was discussed and sample size considerations 
were presented in the enrichment design and randomized 
block design of clinical studies. Most studies performed 
the biomarker analysis using primary tissues rather than 
therapy refractory samples. Dr. Krop suggested that the 
study of circulating tumor cells and circulating DNA can 
also provide relevant information about the progression of 
disease. The question of therapeutic resistance continues to 
be one of the most understudied areas with only a handful 
of validated mechanisms. Therefore, there is a strong need 
to evaluate metastatic tumor samples in refractory patients 
Cancer System Biology: Cancer Transcriptome, 
Proteome and Metabolome
Dr. Anelia Horvath from George Washington 
University shared latest GCGC data on characterization 
of the genetic variance of 17 tumors representing the most 
common breast cancer receptor subtypes: triple-negative 
(TNBC), non-TBNC and HER2-positive breast cancer, 
using whole transcriptome sequencing [1]. This study 
illustrates the power of RNA-sequencing in revealing 
the variation landscape of breast transcriptome and 
exemplifies analytical strategies to explore regulatory 
interactions among cancer relevant molecules. 
Next Dr. Stefan Knap from the University of Oxford 
talked about how structural information has facilitated 
chemical biology programs that aim to develop selective 
inhibitors that can be used as tool molecules to study the 
role of kinases in RNA splicing and structural comparison 
of the generated crystal structures revealed structural 
features that can be utilized for the development of highly 
specific inhibitors. Dr. Knapp research on the development 
of selective kinase inhibitors has focused on Cdc2-like 
kinases (CLKs), which are splicing regulators and found 
to be deregulated in many cancers. The effects of specific 
inhibition of CLK1 on TS splicing in endothelial cells, 
the effect of SRPK2 on VEGF splicing, and the effect of 
DIRK inhibition, were presented as relevant examples of 
kinase inhibitors potential. 
On the last presentation of this session Dr. Sérgio 
Dias from Instituto de Medicina Molecular presented 
recent data showing the metabolic alterations in 
microenvironment gives instructive cues that regulate/
modulate the metastatic potential of cancer cells, using 
models of hematological and solid cancers. Dr. Dias 
focused on how a high fat systemic environment affects 
cancer behavior. He shared recent data showing that mice 
on hypercholesterolemic diet present bigger breast tumors, 
with higher proliferation, migration, and mesenchymal 
traits, and lower adhesion, more prone to progress into 
the central nervous system [18]. Dr. Dias has previously 
shown high cholesterol perturbs the bone marrow 
microenvironment [19]. He also presented data showing 
increased leukemia burden and spread on high cholesterol 
mice, with higher trans-endothelial migration, probably 
due to CX3CR1 induction [20]. 
Need to Integrate Microenvironment and 
Metabolomics with Cancer Genomics
In the final session of this meeting, speakers 
highlighted the importance of tissue microenvironment on 
the comprehension and analysis of cancer genomics data. 
Dr. Sandra Casimiro from Instituto de Medicina Molecular 
focused on the ‘vicious cycle’ of bone metastases and 
on the need to identify and dissect the mechanisms and 
events involved in bone colonization within different sub-
types of breast cancer. This can lead to new prognostic 
and predictive markers, and to new potential therapeutic 
molecules specifically targeting the tumor compartment of 
bone metastases. Dr. Casimiro showed how pre-clinical 
research with cancer cell lines and animal models is being 
translated into clinical models, by sharing gene expression 
signatures of metastases [15], and showed evidence that 
targeting RANKL-RANK pathway may also affect the 
tumor compartment of bone metastases [21]. 
Dr. Fátima Baltazar from the University of 
Minho talked about the expression of monocarboxylate 
transporters (MCTs) and the MCT1/4 chaperone CD147, 
in human cancers [22]. MCT isoforms 1 and 4 mediate 
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the plasma membrane efflux of lactate coupled with a 
proton, playing an important role in the maintenance 
of the metabolic phenotype of tumours. The pattern of 
MCT expression varies with cancer types and MCT 
overexpression has important associations with tumor 
aggressiveness. In general, MCT inhibition in glycolytic 
tumour cells leads to a decrease in lactate production, 
cell proliferation, migration and invasiveness [23]. 
Although MCT activity is essential for the maintenance 
of the metabolic phenotype of tumours, however, MCTs 
are differentially expressed among the solid tumours and 
future strategies of MCT inhibition in cancer treatment 
should take this fact into account. 
Dr. Bruno Silva-Santos from Instituto de Medicina 
Molecular focused on research on gamma-delta T 
lymphocytes, which play key, non-redundant anti-tumor 
roles in animal models of tumor development. Dr. Silva 
Santos also spoke about stress-inducible determinants 
of anti-tumor gamma-delta T cell responses and its 
implications for manipulating lymphocyte lineage in 
cancer immunotherapy. His work has identified markers 
of susceptibility versus resistance to gamma-delta T 
cell-mediated cytotoxicity. Expression and functional 
studies also identified the chemokine CCL2 as a major 
determinant of gamma-delta T cell infiltration into solid 
tumors and counter-receptor CCR2 to infiltrate tumors in 
vivo, where they inhibited tumor cell growth [24]. 
Finally, Dr. João Barata from Instituto de Medicina 
Molecular shared new data on how IL-7 and IL-7R 
constitute an important oncogenic axis in T-cell leukemia, 
underpinning the relevance that both cell-autonomous 
and cell extrinsic cues can have in promoting cancer. 
Dr. Barata showed how IL-7 accelerates human T-ALL 
expansion in vivo [25]; IL-7R mutational activation 
promotes T-ALL [26]; forced wild type IL7R expression 
appears to promote T-cell oncogenesis.
CONCLUSIONS AND ON-GOING GCGC 
TRANSLATIONAL ENDEAVORS
In brief, the meeting fulfilled one of the original 
mission of GCGC to bring its members and associated 
institutions together to review the progress made during 
the last year while bring leaders in the field and local 
students and fellows together to also share their recent 
findings with the GCGC members at-large. Collectively, 
sessions were designed to share the latest information 
in the context of pertinent bottlenecks in a given sub-
themes and present potential solutions to move forward. 
This exercise could be best exemplified by highlighting 
the significance of quality onco-biobanking for asking 
genomic questions as well as validating the outcome 
before it could be implemented to the bedside. There 
was also a lot of excitement to witnessing the changing 
culture in organizing multidisciplinary research teams 
of oncologists, scientists, pathologists and surgeons 
while asking meaningful translational cancer medicine 
questions. The meeting participants also felt the need of 
start better integrating cancer transcriptome with proteome 
to promote targeted cancer therapeutics. Drs. Luis Costa 
and Rakesh Kumar closed the meeting by announcing that 
the next meeting will focus on Epigenome and Cancer 
Medicine and the 4th GCGC meeting and will be held 
at the Kyoto University Graduate School of Medicine, 
Kyoto, Japan in 2014.
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